Perceptive Advisors EWTX Position
Active11-Fund ConvergencePerceptive Advisors increased their position in Edgewise Therapeutics, Inc. (EWTX) in Q4 2025, holding $110.6M worth of shares across 4,457,974 shares.
The position was first reported in Q4 2023 and has been tracked across 9 quarterly 13F filings.
EWTX is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for EDG-7500 in 75 days (Jun 30, 2026), making the timing of Perceptive's position particularly relevant.
Short interest stands at 10.3% of float with 10.5 days to cover, indicating significant bearish positioning against Perceptive's long thesis.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Full company profile →Short Interest
10.3%
10.5 days to cover
Perceptive Advisors EWTX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 4,457,974 | +662,080 | $110.6M |
| Q3 2025 | Decreased | 3,795,894 | -844,055 | $61.6M |
| Q2 2025 | Decreased | 4,639,949 | -1,907,379 | $60.8M |
| Q1 2025 | Increased | 6,547,328 | +3,861,791 | $144.0M |
| Q4 2024 | Increased | 2,685,537 | +355,243 | $71.7M |
| Q3 2024 | Increased | 2,330,294 | +473,877 | $62.2M |
| Q2 2024 | Decreased | 1,856,417 | -463,229 | $33.4M |
| Q1 2024 | Increased | 2,319,646 | +1,764,091 | $42.3M |
| Q4 2023 | New | 555,555 | +555,555 | $6.1M |
Frequently Asked Questions
Does Perceptive Advisors own EWTX?
Yes. As of Q4 2025, Perceptive Advisors holds 4,457,974 shares of Edgewise Therapeutics, Inc. (EWTX) valued at $110.6M. This data comes from their SEC 13F filing.
How many hedge funds own EWTX?
11 specialist biotech hedge funds currently hold EWTX, including OrbiMed Advisors, RA Capital Management, Baker Bros. Advisors and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy EWTX?
Perceptive Advisors's position in EWTX was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's EWTX position increasing or decreasing?
Perceptive Advisors increased their EWTX position in the most recent quarter, adding 662,080 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
EWTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →